Want to monitor RAPT?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor RAPTrapt therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. rapt has discovered and advanced two unique drug candidates, flx475 and rpt193, each targeting c-c motif chemokine receptor 4 (ccr4), for the treatment of cancer and inflammation, respectively.